Liver Fibrosis – Pipeline Review, H2 2012

Publisher Name :
Date:31-Oct-2012
No. of pages: 87
Inquire Before Buying

Liver Fibrosis – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, ‘Liver Fibrosis – Pipeline Review, H2 2012′, provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Liver Fibrosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Liver Fibrosis. Liver Fibrosis – Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Liver Fibrosis.
- A review of the Liver Fibrosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Liver Fibrosis pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Liver Fibrosis.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Liver Fibrosis pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Liver Fibrosis – Pipeline Review, H2 2012

Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Liver Fibrosis Overview 9
Therapeutics Development 10
An Overview of Pipeline Products for Liver Fibrosis 10
Liver Fibrosis Therapeutics under Development by Companies 12
Liver Fibrosis Therapeutics under Investigation by Universities/Institutes 14
Late Stage Products 15
Comparative Analysis 15
Mid Clinical Stage Products 16
Comparative Analysis 16
Early Clinical Stage Products 17
Comparative Analysis 17
Discovery and Pre-Clinical Stage Products 18
Comparative Analysis 18
Liver Fibrosis Therapeutics - Products under Development by Companies 19
Liver Fibrosis Therapeutics - Products under Investigation by Universities/Institutes 20
Companies Involved in Liver Fibrosis Therapeutics Development 21
Bristol-Myers Squibb Company 21
Gilead Sciences, Inc. 22
FibroGen, Inc. 23
Silence Therapeutics plc. 24
Genfit 25
La Jolla Pharmaceutical Company 26
LG Life Sciences, Ltd 27
Digna Biotech, S.L. 28
7TM Pharma A/S 29
GenKyoTex S.A. 30
Angion Biomedica Corp. 31
Virobay Inc. 32
Liver Fibrosis - Therapeutics Assessment 33
Assessment by Monotherapy Products 33
Assessment by Combination Products 34
Assessment by Route of Administration 35
Assessment by Molecule Type 37
Drug Profiles 39
FG-3019 - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
TM-38837 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
GFT-505 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
P-17 Systemic - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
GM-CT-01 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
VBY-376 - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
BB-3 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
GKT-137831 - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
candesartan cilexetil - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
irbesartan - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
GS-6624 - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
CIGB-500 - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
AB-0023 - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
AM-095 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
Raltegravir + Ritonavir-Boosted Protease Inhibitor - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
Cytopro - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
GM-CT-02 - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
GR-MD-02 - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
GR-MD-01 - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
ANG-4011 - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
F-351 - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
Drug For Liver Diseases - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
ANG-3298 - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
LC-280126 - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
Liver Fibrosis Therapeutics - Drug Profile Updates 69
Liver Fibrosis Therapeutics - Discontinued Products 78
Liver Fibrosis Therapeutics - Dormant Products 79
Liver Fibrosis - Product Development Milestones 80
Featured News & Press Releases 80
Aug 07, 2012: New Drug Successfully Halts Fibrosis In Animal Model Of Liver Disease, Study Reports 80
Aug 07, 2012: Galectin Therapeutics Plans Clinical Trials For Early 2013 To Treat Fatty Liver Disease With Advanced Fibrosis After Recent FDA Meeting 80
Jul 23, 2012: Galectin Therapeutics Receives US Patent for Potential Treatment for Chronic Liver Disease with Fibrosis And Cirrhosis 81
May 10, 2012: Genfit Announces Preclinical Data Of GFT505 Promotes Liver Fibrosis Regression 82
Dec 16, 2011: Galectin Therapeutics Presents Preclinical Data On Treatment Of Fatty Liver Disease And Fibrosis At EASL 82
Nov 02, 2011: Promedior Announces Presentation Of Preclinical Data At AASLD Demonstrating That Pentraxin-2 Suppresses Liver Fibrosis 83
Jul 12, 2011: GENFIT Announces First Results Of GFT505-210-5 Clinical Trial In Diabetic Patients 83
Apr 11, 2011: Fragment Of RegeneRx's Tß4 Inhibits Activation Of Liver Cells Responsible Fibrosis And Scar Formation 84
Oct 20, 2010: GNI Receives F351 Patent Allowance in Japan 84
Oct 14, 2010: FibroGen Initiates Phase II Clinical Study To Evaluate Efficacy Of FG-3019 In Reversing Liver Fibrosis 85
Appendix 86
Methodology 86
Coverage 86
Secondary Research 86
Primary Research 86
Expert Panel Validation 86
Contact Us 87
Disclaimer 87

List of Tables
Number of Products Under Development for Liver Fibrosis, H2 2012 10
Products under Development for Liver Fibrosis - Comparative Analysis, H2 2012 11
Number of Products under Development by Companies, H2 2012 13
Number of Products under Investigation by Universities/Institutes, H2 2012 14
Comparative Analysis by Late Stage Development, H2 2012 15
Comparative Analysis by Mid Clinical Stage Development, H2 2012 16
Comparative Analysis by Early Clinical Stage Development, H2 2012 17
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 18
Products under Development by Companies, H2 2012 19
Products under Investigation by Universities/Institutes, H2 2012 20
Bristol-Myers Squibb Company, H2 2012 21
Gilead Sciences, Inc., H2 2012 22
FibroGen, Inc., H2 2012 23
Silence Therapeutics plc., H2 2012 24
Genfit, H2 2012 25
La Jolla Pharmaceutical Company, H2 2012 26
LG Life Sciences, Ltd, H2 2012 27
Digna Biotech, S.L., H2 2012 28
7TM Pharma A/S, H2 2012 29
GenKyoTex S.A., H2 2012 30
Angion Biomedica Corp., H2 2012 31
Virobay Inc., H2 2012 32
Assessment by Monotherapy Products, H2 2012 33
Assessment by Combination Products, H2 2012 34
Assessment by Stage and Route of Administration, H2 2012 36
Assessment by Stage and Molecule Type, H2 2012 38
Liver Fibrosis Therapeutics - Drug Profile Updates 69
Liver Fibrosis Therapeutics - Discontinued Products 78
Liver Fibrosis Therapeutics - Dormant Products 79

List of Figures
Number of Products under Development for Liver Fibrosis, H2 2012 10
Products under Development for Liver Fibrosis - Comparative Analysis, H2 2012 11
Products under Development by Companies, H2 2012 12
Products under Investigation by Universities/Institutes, H2 2012 14
Late Stage Products, H2 2012 15
Mid Clinical Stage Products, H2 2012 16
Early Clinical Stage Products, H2 2012 17
Discovery and Pre-Clinical Stage Products, H2 2012 18
Assessment by Monotherapy Products, H2 2012 33
Assessment by Combination Products, H2 2012 34
Assessment by Route of Administration, H2 2012 35
Assessment by Stage and Route of Administration, H2 2012 36
Assessment by Molecule Type, H2 2012 37
Assessment by Stage and Molecule Type, H2 2012 38

  • Challenges in the Tourism Industry in Thailand
    Thailand has always been a popular tourist destination and tourism provides a major boost to the country’s economy. Bangkok, Hua Hin, Krabi, Samui, Phuket and Cha Am are some of the most attractive tourist destinations in the country. In 2012, Thailand had a very high number of arrivals. Even the number of Thai citizens who [...]
  • Future of the US Consumer Electronics Market
    The market for consumer electronics has been growing steadily. Some of the factors that are contributing to the growth in the market are technological advancement, rise in disposable income and increasing demand for new products. During 2012, consumer electronics market in the US demonstrated positive expansion, although the growth rate slowed down considerably following the [...]
  • Overview of the Global Retail Market
    The global retail industry continued to grow despite the difficult economic conditions in the world. In the fiscal year of 2011, sales-weighted, currency-adjusted revenue rose by 5.1% to $4.271 trillion for the world’s top 250 retailers. According to GRDI (Global Retail Development Index), in 2013 Brazil occupied the top spot in retail development. Chile and [...]
  • Bright Future Predicted for the Tourism Industry in Singapore
    Travel and tourism industry in Singapore has been growing at a steady rate and is considered to be a major contributor to the economic growth of the country. In 2012, Singapore’s IVA (International Visitors Arrivals) reached a record high of 14.5 million, with a growth rate of 10.1% year-on-year. In recent years, inbound travel to [...]
  • Potential of Staffing Market in United States
    The staffing industry places individuals into contract, temporary and permanent positions in firms around the world. Major staffing markets include France, Spain, Italy and Japan as well as many emerging markets. Temporary staffing around the world has been growing, but in US temporary market has been flat since 2006. The majority of staffing revenue majorly [...]
  • Diagnostic X-ray Imaging Market worth $4.0 billion by 2020
  • GlobalData estimates that the global diagnostic X-ray imaging market, worth $2.4 billion in 2012, will reach almost $4.0 billion by 2020, increasing at a Compound Annual Growth Rate (CAGR) of 6.7% during the forecast period. Many players are active in …

  • Graft-Versus-Host Disease Market Forecast to 2023
  • Graft-versus-host disease (GVHD) is a common complication of allogeneic hematopoietic stem cell transplantation (HSCT) that occurs when the donated (graft) cells are rejected and attack the host’s cells as foreign. GVHD can progress from mild to severe forms as either …

  • Chronic Lymphocytic Leukemia (CLL) Treatment Market worth $3.3 billion by 2018
  • New Entrants to Boost Chronic Lymphocytic Leukemia Treatment Market Value to $3.3 Billion by 2018, says GlobalData. The introduction of several new drugs will accelerate growth in the Chronic Lymphocytic Leukemia (CLL) treatment market, from $1.4 billion in 2013 to …

  • Global Biosimilars Market to Grow at a CAGR of 8.3%, to reach $262 billion by 2019
  • Lucrative Biosimilars Space to Erode Biologics Market from 2019, says GlobalData The increasing prevalence of biosimilars will have a noticeably negative impact on the biologics market beyond 2019, despite an initial projected Compound Annual Growth Rate (CAGR) of 8.3%, taking …

  • Saudi Pharmaceutical Market worth $5.9 billion by 2020
  • A high burden of chronic diseases, improving regulatory guidelines and the launch of new products will provide the necessary impetus for the growth of the pharmaceutical market in Saudi Arabia The Saudi pharmaceutical market is one of the largest markets …

  • 2014 Deep Research Report on Global and China Laser Scanning Confocal Microscope Industry
    Published: 23-Jul-2014        Price: US $2200 Onwards        Pages: 187
    This is a professional and depth research report on Global and China Laser Scanning Confocal Microscope industry. The report firstly introduced Laser Scanning Confocal Microscope basic information included Laser Scanning Confocal Microscope definition classification application industry chain structure industry overview; Laser Scanning Confocal Microscope production and sales by manufacturers by technology by regions or countries, and also introduced global key manufacturers manufacturing bases ......
  • Czech Republic Pharmaceuticals and Healthcare Report Q3 2014
    Published: 23-Jul-2014        Price: US $1295 Onwards        Pages: 112
    BMI View: Pharmaceutical sales will decline further this year, following the release of poor sales data from the first quarter. Price declines throughout Europe and restructuring of the healthcare system will continue to impact demand within the Czech Republic. We also believe the new centre-left coalition government poses downside risk to our forecasts given its commitment to containing healthcare costs and improving access to medicines. Despite these concerns, our view is more optimistic over ......
  • Denmark Pharmaceuticals and Healthcare Report Q3 2014
    Published: 23-Jul-2014        Price: US $1295 Onwards        Pages: 58
    BMI View: Like many other Western European countries, Denmark's expanding elderly population will ensure that demand for quality healthcare remains high and will be a key driving factor for its wellestablished, albeit relatively small, pharmaceutical market. The robust demand for healthcare services will see the Danish government continue to adapt strategies and cost-containment measures to manage increasing healthcare costs. Despite this, we believe the country's high per-capita drug expenditur......
  • France Infectious Disease Molecular Diagnostics Market: Country Forecasts, Supplier Shares, Emerging Technologies, Competitive Landscape
    Published: 23-Jul-2014        Price: US $4350 Onwards        Pages: 615
    This new study from Venture Planning Group contains 615 pages, 26 tables, and is designed to help current suppliers and potential market entrants identify and evaluate emerging opportunities in the infectious disease molecular diagnostics market during the next five years.Report HighlightsBusiness and technological trends in major markets Five-year test volume and sales forecasts Market shares of leading competitors Feature comparison of major analyzers Strategic profiles of lea......
  • Iraq Pharmaceuticals and Healthcare Report Q3 2014
    Published: 23-Jul-2014        Price: US $1295 Onwards        Pages: 83
    BMI View: Thanks to the government's expansionary fiscal policy, spending on education, health and public services will increase. The Iraqi government has reportedly pledged to invest USD12bn into healthcare expansions in 2014, and the Ministry of Health recently awarded 18 health project contracts worth USD276mn. In addition, new restrictions aim to end the chaos in which materials have entered the country in previous years, targeting control over drug policy and ensuring the supply of medicine......
  • Kuwait Pharmaceuticals and Healthcare Report Q3 2014
    Published: 23-Jul-2014        Price: US $1295 Onwards        Pages: 123
    BMI View: Despite upcoming by-elections, Kuwait's economy is forecast to post moderate growth in 2014, and the prospects for consumption remain bright. While price harmonisation across the GCC is likely to have a significant impact on margins in the sector, implementation remains slow. Concern over fake generic drugs presents opportunities for the segment in the country, and has spurred partnership agreements with local distributors in the region. Healthcare spending will remain strained as the ......
  • Malaysia Pharmaceuticals and Healthcare Report Q3 2014
    Published: 23-Jul-2014        Price: US $1295 Onwards        Pages: 145
    BMI View: We remain generally optimistic towards Malaysia's commitment to provide better quality and access to healthcare, as the government plans to expand and upgrade its hospital network. However, we have downgraded Malaysia's pharmaceutical sales forecast due to a slowdown in pharmaceutical trade in 2013. The country's slower economic growth in 2014, coupled with the fact that investment in the pharmaceuticals sector will take longer than expected to bring returns, are downside risks to our ......
  • ConMed: Organization, Facilities, Technologies, Products, Marketing, R&D, Strategies
    Published: 23-Jul-2014        Price: US $1850 Onwards        Pages: 25
    A strategic assessment of ConMed, one of the world's leading orthopedics companies, provides significant competitor information, analysis, and insight critical to the development and implementation of effective marketing and R&D programs. The report presents a comprehensive analysis of the company's performance, capabilities, goals and strategies in the global orthopedics market.......
  • Portugal Pharmaceuticals and Healthcare Report Q3 2014
    Published: 23-Jul-2014        Price: US $1295 Onwards        Pages: 116
    BMI View: Faster-than-expected economic growth last quarter has led us to revise our healthcare and pharmaceutical forecasts slightly upwards. As forecast previously, BMI expects Portugal's healthcare market to return to growth in 2015, while pharmaceuticals will not return to growth until 2019. This is because while Portugal exited its bailout programme in May 2014 without the need for a new financial package, government austerity measures are likely to curb pharmaceutical reimbursement. Portug......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs